Seiwert Scott 4

4 · INTERMUNE INC · Filed May 16, 2011

Form 4

Period: 2011-05-12

VP, Rsearch/ Preclinical Dev.

Transactions

Exercise/Conversion
Common Stock
2011-05-12$15.40/sh+9,500$146,300→ 72,765 total
Exercise/Conversion
Common Stock
2011-05-12$11.93/sh+15,000$178,950→ 87,765 total
Exercise/Conversion
Common Stock
2011-05-12$22.16/sh+22,980$509,237→ 118,413 total
Exercise/Conversion
Stock Option (Right to Buy)
2011-05-12−15,000→ 0 total
Exercise: $11.93Exp: 2015-05-26→ Common Stock (15,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2011-05-12−5,468→ 2,032 total
Exercise: $15.34Exp: 2018-05-13→ Common Stock (5,468 underlying)
Exercise/Conversion
Common Stock
2011-05-12$16.93/sh+2,200$37,246→ 95,433 total
Exercise/Conversion
Stock Option (Right to Buy)
2011-05-12−9,500→ 0 total
Exercise: $15.40Exp: 2016-06-30→ Common Stock (9,500 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2011-05-12−22,980→ 0 total
Exercise: $22.16Exp: 2016-12-12→ Common Stock (22,980 underlying)
Exercise/Conversion
Common Stock
2011-05-12$15.34/sh+5,468$83,879→ 93,233 total
Sale
Common Stock
2011-05-12$39.13/sh−71,443$2,795,229→ 46,970 total
Exercise/Conversion
Stock Option (Right to Buy)
2011-05-12−2,200→ 0 total
Exercise: $16.93Exp: 2013-06-16→ Common Stock (2,200 underlying)

Footnotes (3)

[F1]Represents the weighted average sale price for the entire number of shares sold. The sale prices range from $38.75 to $39.35 per share. Full information on the numbers of shares sold at each sale price is available upon request.
[F2]Fully exercisable.
[F3]Twenty-five percent (25%) of the total number of shares subject to the stock option vest and become exercisable on the first anniversary of the grant date. The remainder of the option shares vests and becomes exercisable cumulatively in equal monthly installments over the following thirty-six (36) months.

Documents

1 file